Clene Inc. (CLNN) stock
CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.42+0.20 (+6.21%)
Close on Nov 18, 2026Market cap $43.94MP/E –Yield –
Clene net income
Net income is the profit left for shareholders after every expense, interest and tax.
Clene's net income for the twelve months ending Jun 30, 2026 was -$39.52M. For fiscal 2025 it was -$26.17M. The highest annual figure on record is -$9.74M in fiscal 2021.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.17M | – |
| FY2024 | Dec 31, 2024 | -$39.40M | – |
| FY2023 | Dec 31, 2023 | -$49.50M | – |
| FY2022 | Dec 31, 2022 | -$29.92M | – |
| FY2021 | Dec 31, 2021 | -$9.74M | – |
| FY2020 | Dec 31, 2020 | -$19.28M | – |
| FY2019 | Dec 31, 2019 | -$16.16M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$13.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.23M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.78M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$751.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.08M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.17M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.42M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.14M | -668.5% |
| Q1 FY2023 | Mar 31, 2023 | -$11.77M | -140.7% |
| Q2 FY2022 | Jun 30, 2022 | -$4.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.35M | – |
| Q4 FY2021 | Dec 31, 2021 | $4.42M | +468.5% |
| Q3 FY2021 | Sep 30, 2021 | $28.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.35M | – |
| Q1 FY2021 | Mar 31, 2021 | -$39.76M | – |
| Q4 FY2020 | Dec 31, 2020 | $778.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.30M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.82M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.94M | – |
See a number that looks wrong?